Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total transaction of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares in the company, valued at $1,029,132. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Boston Scientific Corporation (NYSE BSX) traded up $0.27 during midday trading on Wednesday, reaching $27.25. 5,864,654 shares of the company’s stock traded hands, compared to its average volume of 11,294,664. Boston Scientific Corporation has a 1-year low of $23.29 and a 1-year high of $29.93. The stock has a market capitalization of $37,420.00, a P/E ratio of 44.67, a PEG ratio of 1.96 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.27 earnings per share. equities research analysts expect that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Commerce Bank grew its position in Boston Scientific by 17.7% during the second quarter. Commerce Bank now owns 9,803 shares of the medical equipment provider’s stock valued at $272,000 after acquiring an additional 1,471 shares during the last quarter. Schroder Investment Management Group grew its position in Boston Scientific by 3.2% during the second quarter. Schroder Investment Management Group now owns 275,180 shares of the medical equipment provider’s stock valued at $7,656,000 after acquiring an additional 8,623 shares during the last quarter. Private Advisor Group LLC grew its position in Boston Scientific by 26.6% during the second quarter. Private Advisor Group LLC now owns 19,376 shares of the medical equipment provider’s stock valued at $534,000 after acquiring an additional 4,069 shares during the last quarter. Commonwealth Bank of Australia grew its position in Boston Scientific by 8.7% during the second quarter. Commonwealth Bank of Australia now owns 73,572 shares of the medical equipment provider’s stock valued at $2,038,000 after acquiring an additional 5,919 shares during the last quarter. Finally, CIBC World Markets Inc. bought a new position in Boston Scientific during the second quarter valued at approximately $663,000. 90.51% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently issued reports on the stock. Barclays restated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a research report on Wednesday, January 10th. BMO Capital Markets reiterated a “buy” rating and set a $31.00 target price on shares of Boston Scientific in a research report on Wednesday, November 29th. Needham & Company LLC upgraded shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and boosted their price target for the company from $25.04 to $32.00 in a research note on Friday, December 8th. Oppenheimer restated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. Finally, Canaccord Genuity decreased their price target on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $31.00.
COPYRIGHT VIOLATION WARNING: “Boston Scientific Corporation (BSX) SVP Sells $139,104.00 in Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/17/david-a-pierce-sells-5152-shares-of-boston-scientific-corporation-bsx-stock.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.